SAN DIEGO, CA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)SANFORD LABORATORIES FOR INNOVATIVE MEDICINES, founded in 2021, is a mid-sized nonprofit in the Arts, Culture & Humanities sector that reported $12.8M in total revenue in fiscal year 2024. The organization ran a surplus of $4.8M, a strong 38% operating margin.
SANFORD LABORATORIES FOR INNOVATIVE MEDICINES (SANFORD LABS) IS A NOT-FOR-PROFIT BIOMEDICAL RESEARCH ORGANIZATION WITH A MISSION TO DISCOVER AND DELIVER NEXT-GENERATION PRECISION MEDICINES TO IMPROVE THE LIVES OF PATIENTS IN NEED.
SANFORD LABORATORIES FOR INNOVATIVE MEDICINES (SANFORD LABS) IS AN INDEPENDENT, NOT-FOR-PROFIT COLLABORATIVE HUB WITH A MISSION TO ACCELERATE THE DEVELOPMENT OF NOVEL MOLECULAR MEDICINES FROM...
SANFORD LABORATORIES FOR INNOVATIVE MEDICINES (SANFORD LABS) IS AN INDEPENDENT, NOT-FOR-PROFIT COLLABORATIVE HUB WITH A MISSION TO ACCELERATE THE DEVELOPMENT OF NOVEL MOLECULAR MEDICINES FROM SCIENTIFIC DISCOVERY TO THE CLINIC. OUR CURRENT RESEARCH IS FOCUSED ON RNA THERAPEUTICS, A RAPIDLY EXPANDING CLASS OF DRUGS WITH THE POTENTIAL TO PROGRESS QUICKLY FROM CONCEPT TO PATIENT AND CHANGE THE STANDARD OF CARE FOR MANY LIFE-THREATENING DISEASES. (CONTINUED ON SCHEDULE O).OUR UNIQUE OPERATING MODEL FILLS A CRITICAL GAP FOR TRANSLATIONAL RESEARCH THAT DOES NOT FIT TRADITIONAL ACADEMIC LABS AND YET IS TOO EARLY FOR VENTURE OR INDUSTRY INVESTMENT. OUR RESEARCH TEAMS, LED BY TEAMS OF ENTREPRENEURIAL SCIENTISTS, ARE ORGANIZED AROUND THERAPEUTIC APPROACHES AND PLATFORM TECHNOLOGIES WITH BROAD APPLICABILITY TO A RANGE OF DISEASES, THUS ENABLING THE EFFICIENT PROTOTYPING OF MULTIPLE NEW MEDICINES IN PARALLEL. IN ADDITION TO OUR INTERNAL RESEARCH, WE ARE ACTIVELY FORGING COLLABORATIONS ACROSS THE DYNAMIC LIFE SCIENCE ECOSYSTEM AND AIM TO ENHANCE SAN DIEGO'S LEADERSHIP AS A WORLD-CLASS CLUSTER IN RNA BIOLOGY AND MEDICINES.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $12,779,638 | $12,532,763 | +0.0% |
| Expenses | $7,949,869 | $3,933,217 | +1.0% |
| Net Income | $4,829,769 | $8,599,546 | -0.4% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| KRISTIINA VUORI MD PHD | PRESIDENT/BOARD MEMBER | 6.00 |
Officer
Director
|
$69,389 | $0 | $69,389 |
| KNOX BELL | SECRETARY/BOARD MEMBER | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| EDWARD HOLMES MD | CHAIR | 1.00 |
Director
|
$0 | $0 | $0 |
| MICHAEL DOLLAR | CFO | 40.00 |
Officer
|
$323,120 | $25,633 | $348,753 |
| WENHAO JIN | GROUP LEADER | 40.00 |
Highest
|
$168,693 | $18,752 | $187,445 |
| JASON KREISBERG | ASSOCIATE DIRECTOR, SS&P | 40.00 |
Highest
|
$153,472 | $15,982 | $169,454 |
| DANIEL A LORENZ | GROUP LEADER | 40.00 |
Highest
|
$166,673 | $13,173 | $179,846 |
| SVEN SEBASTIAN J MARKMILLER | GROUP LEADER & STRATEGY ADVISOR | 40.00 |
Highest
|
$189,669 | $29,328 | $218,997 |
| CONNIE MARTINEZ | HUMAN RESOURCES DIRECTOR | 40.00 |
Highest
|
$157,583 | $27,257 | $184,840 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | No data | No data | No data | No data |
| 2024 | $12,779,638 | $7,949,869 | $20,157,004 | $4,829,769 |
| 2023 | $12,532,763 | $3,933,217 | $26,076,643 | $8,599,546 |
| 2022 | $2,001,082 | $15,825 | $12,004,057 | $1,985,257 |
Compare SANFORD LABORATORIES FOR INNOVATIVE MEDICINES with other nonprofits in California and across the country.